Colorectal Cancer Therapeutics Market

Colorectal Cancer Therapeutics Market by Drug Classes (Chemotherapy [Antimetabolites and Alkylating Agents], Immunotherapy [Biologic Response Modifiers, Colony Stimulating Factors, Tumor Vaccines, and Monoclonal Antibodies], and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1017
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 187
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global colorectal cancer therapeutics market size is expected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of colon and rectal cancer.
 

Colorectal Cancer Therapeutics Market Key Takeaways


Colorectal cancer (CRC) is the third most common type of cancer, after lung and breast cancer. Colorectal cancer also called as bowel cancer and colon cancer. It is a type of cancer which affects the colon and the rectum by uncontrolled and abnormal division of cells leading to the formation of a malignant tumor. In-vitro colorectal cancer screening tests are done to check symptoms and presence of colorectal cancer. In this test prevalence of colorectal cancer in patients is confirmed by understanding the progression and nature of this cancer. Exact causes of CRC are unspecified. Though, various environmental and genetic factors are responsible for rising the risk of disease development.

Based on the American Cancer Society, in the U.S., around 1 out of 21 men and 1 in 23 women are projected to progress colorectal cancer in their lifetime. However, prevalence of colorectal cancer is reducing over the last few years because of advanced diagnostics and screening along with improved treatment. Emergence of front-line therapies and increasing initiatives by government are projected to aid the market. Increasing adoption of unhealthy habits, inactive lifestyle habits, and rising consumption of alcohol and tobacco smoking are responsible for inflammatory intestinal conditions which leads rising cases of colorectal cancer.

Acceptance of advanced therapies is rising. Some of the advanced therapies includes Avastin (bevacizumab), Erbitux (cetuximab), and Stivarga (regorafenib), which helps the expansion of the market. Patent of major products such as Avastin, Vectibix, and Zaltrap are projected to lose over the forecast period. Hence, expiration of patent leads to increase in penetration of biosimilars. Amgen and Allergan’s Mvasi were first biosimilar to Avastin approved in U.S. and Europe. Due to which biosimilars mark the entry into oncology field. Other biosimilars such as bevacizumab and cetuximab are anticipated to impact branded sales after launch.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing prevalence of colon and rectal cancer is one of the major factors responsible for the growth of the market over the forecast period.
  • Rising awareness about disease among people and increasing aging population are projected to boost the market expansion in the coming years.
  • Favorable government initiatives and free or low-cost treatment at government hospitals are anticipated to drive the growth of the market.
  • Easy accessibility and availability of treatment options, and more targeted therapies are key factors responsible for the expansion of the market during the forecast period.
  • Early detection and treatment, emergence of more front-line therapies and favorable reimbursement policies are estimated to fuel the market growth.
  • Rising acceptance of advanced therapies and increasing launch of promising pipeline candidates are expected to propel the market growth over the forecast period.
  • Lack of awareness about cancer among people and a smaller number of trained staff are anticipated to impede the market expansion in the coming years.
  • No early detection and cultural difference, and reluctance in adoption of colorectal cancer medications are factors responsible for hampering the market growth.

Scope of the Report

The report on the global colorectal cancer therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Colorectal Cancer Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug Classes (Chemotherapy [Antimetabolites and Alkylating Agents], Immunotherapy [Biologic Response Modifiers, Colony Stimulating Factors, Tumor Vaccines, and Monoclonal Antibodies], and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Amgen; Bayer; Bristol-Myers Squibb; Eli Lilly; Merck; Sanofi; Abbott Laboratories; Epigenomics AG; F. Hoffmann-La Roche AG; Siemens Healthineers; and Novigenix SA

 

Market Segment Insights

Immunotherapy segment is projected to hold a major market share
Based on drug classes, the colorectal cancer therapeutics market is divided into chemotherapy, immunotherapy, and others. The chemotherapy segment is further bifurcated into antimetabolites and alkylating agents. The immunotherapy segment is further subdivided into biologic response modifiers (BRF), colony stimulating factors (CSF), tumor vaccines, and monoclonal antibodies.

The immunotherapy segment is expected to hold a key share of the market during the forecast period. Immunotherapy segment has some adverse effects than chemotherapy segment. Chemotherapy has toxic side effects and non-specificity, because of which adoption of immunotherapeutic is increasing. Immunotherapy fights with cancer cells by using human immune system. In this type many different drugs are present across the globe. The immunotherapy segment comprises of checkpoint inhibitors and targeted antibodies. Increasing research and development, rising awareness about cancer therapeutics among people, and advantages of immunotherapy are expected to drive the growth of the segment. Furthermore, growing therapeutic applications of immunotherapeutic agents to colorectal cancer is anticipated to propel the market expansion over the forecast period.
 

Colorectal Cancer Therapeutics Market By Drug Classes


North America is expected to dominate the market
On the basis of regions, the colorectal cancer therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increase in incidences of colorectal cancer in the region, inflated medicine prices, and increase in treatment rates. According to the American Cancer Society, in 2017, in the U.S., approximately 39,000 new rectal cancer cases and around 95,500 new colon cancer cases were reported. This shows that incidence of colorectal cancer is rising in the U.S. which is expected to boost the regional market growth in the coming years.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to availability and accessibility of effective treatment options, high unmet clinical needs of patients, and increasing disposable income.

Japan is slated to exhibit the highest CAGR among the seven major markets. This growth can be attributed to high unmet clinical needs of patients, rising disposable income, and availability of effective treatment options.
 

Colorectal Cancer Therapeutics Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Colorectal Cancer Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Colorectal Cancer Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Colorectal Cancer Therapeutics Market - Supply Chain
  4.5. Global Colorectal Cancer Therapeutics Market Forecast
     4.5.1. Colorectal Cancer Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Colorectal Cancer Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Colorectal Cancer Therapeutics Market Absolute $ Opportunity
5. Global Colorectal Cancer Therapeutics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Colorectal Cancer Therapeutics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
6. North America Colorectal Cancer Therapeutics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Colorectal Cancer Therapeutics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
7. Latin America Colorectal Cancer Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Colorectal Cancer Therapeutics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
8. Europe Colorectal Cancer Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Colorectal Cancer Therapeutics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
9. Asia Pacific Colorectal Cancer Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Colorectal Cancer Therapeutics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
10. Middle East & Africa Colorectal Cancer Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Colorectal Cancer Therapeutics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Colorectal Cancer Therapeutics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Colorectal Cancer Therapeutics Market: Market Share Analysis
  11.2. Colorectal Cancer Therapeutics Distributors and Customers
  11.3. Colorectal Cancer Therapeutics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Amgen
     11.4.2. Bayer
     11.4.3. Bristol-Myers Squibb
     11.4.4. Eli Lilly
     11.4.5. Merck
     11.4.6. Sanofi
     11.4.7. Abbott Laboratories
     11.4.8. Epigenomics AG
     11.4.9. F. Hoffmann-La Roche AG
     11.4.10. Siemens Healthineers
     11.4.11. Novigenix

Segments Covered in the Report
The global colorectal cancer therapeutics market has been segmented on the basis of

Drug Classes

  • Chemotherapy
    • Antimetabolites
    • Alkylating Agents
  • Immunotherapy
    • Biologic Response Modifiers (BRF)
    • Colony Stimulating Factors (CSF)
    • Tumor Vaccines
    • Monoclonal Antibodies
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Amgen
  • Bayer
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck
  • Sanofi
  • Abbott Laboratories
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers
  • Novigenix SA


 

Key players competing in the colorectal cancer therapeutics market are Amgen; Bayer; Bristol-Myers Squibb; Eli Lilly; Merck; Sanofi; Abbott Laboratories; Epigenomics AG; F. Hoffmann-La Roche AG; Siemens Healthineers; and Novigenix SA. Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
 

Colorectal Cancer Therapeutics Market By Key Players

Buy Report